Martine A. Rothblatt, Chairperson and CEO, has demonstrated a clear selling bias in her recent trading activity involving United Therapeutics Corporation (UTHR), the sole company in her transaction history. Over 556 reported trades, Rothblatt has sold $242.5 million worth of shares compared to $64.5 million in buys, with all 24 of her most recent transactions being sales. The bulk of this activity occurred in late March 2026, with multiple disposals on March 27 and March 30. The March 30 sales ranged from smaller transactions like $50,293.13 and $46,539.20 to significantly larger dispositions, including $1,023,637.95 and $1,053,112.13. That same day, Rothblatt also reported a market purchase worth $1,387,285, though this was overshadowed by the aggregate sell-side volume. Earlier, on March 27, she executed six sales with values between $85,519.20 and $478,992.11. The pattern suggests ongoing monetization of her UTHR position, with no recent acquisitions outside the single March 30 buy. The transactions reflect a disciplined approach, with sales executed at varying scales rather than as a single block, potentially indicating a structured divestment strategy.
AI-assisted summary